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Abstract
Our group has previously reported that the majority of human melanomas (N60%) express the metabotropic glutamate
receptor 1 (GRM1) and that the glutamate release inhibitor riluzole, a drug currently used to treat amyotrophic lateral
sclerosis, can induce apoptosis in GRM1-expressing melanoma cells. Our group previously reported that in vitro riluzole
treatment reduces cell growth in three-dimensional (3D) soft agar colony assays by 80% in cells with wildtype
phosphoinositide 3-kinase (PI3K) pathway activation. However, melanoma cell lines harboring constitutive activating
mutations of the PI3K pathway (PTEN and NRAS mutations) showed only a 35% to 40% decrease in colony formation in
soft agar in the presence of riluzole. In this study, we have continued our preclinical studies of riluzole and its effect on
melanoma cells alone and in combination with inhibitors of the PI3 kinase pathway: the AKT inhibitor, API-2, and the
mammalian target of rapamycin (mTOR) inhibitor, rapamycin. We modeled these combinatorial therapies on various
melanoma cell lines in 3D and 2D systems and in vivo. Riluzole combinedwithmTOR inhibition ismore effective at halting
melanoma anchorage-independent growth and xenograft tumor progression than either agent alone. PI3K signaling
changes associatedwith this combinatorial treatment shows that 3D (nanoculture) modeling of cell signalingmore closely
resembles in vivo signaling than monolayer models. Riluzole combined with mTOR inhibition is effective at halting tumor
cell progression independent of BRAF mutational status. This makes this combinatorial therapy a potentially viable
alternative for metastatic melanoma patients who are BRAF WT and are therefore ineligible for vemurafenib therapy.
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Introduction
Melanoma, a malignancy of the pigment producing melanocytes in the
skin, is the fifth most common malignancy in the United States.
In 2014, there were an estimated 76,000 new cases of melanoma and
approximately 10,000 deaths [1]. Early detection followed by surgical
excision is the most definitive treatment for in situ or early stage
malignancy and has a high curative rate [2]. However, therapeutic
options for patients with late-stage melanoma are limited [3,4].
New immunotherapies and targeted therapies (e.g., BRAF inhibitors) in
melanoma shownew clinical promise. However, despite these advances,
most patients undergoing these new treatments will have progression of
disease within 2 to 6 months [5,6]. Therefore, continuing to identify
new treatment regimens for this patient population is critically
important. Developing new therapies for melanoma depends on
identifying new molecular targets that are necessary for melanocyte
transformation and progression. Metabotropic glutamate receptor 1
(GRM1) has been implicated in melanomagenesis and has become a
new promising target for melanoma therapy [7].
GRMs are a family of seven transmembrane domain G-protein–
coupled receptors. Currently, eight different isoforms have been
reported and classified to three different groups according to their
sequence homology and responses to agonists/antagonists. GRMs
are predominantly expressed in the central nervous system and are
essential for memory and learning. GRM1 and GRM5 are members
of group I of GRMs and are coupled to Gq proteins. Stimulated by
their natural ligand, glutamate, group I receptors activate phospho-
lipase C that stimulates polyphosphoinositide hydrolysis leading to
inositol (1,4,5)-triphosphate and diacylglycerol, which function as
second messengers to increase intracellular calcium release from
endoplasma reticulum and activate protein kinase C, respectively [8].
Numerous studies have implicated different isoforms of GRM
expression in various malignancies including gliomas, melanomas,
colorectal adenocarcinoma, and osteosarcoma [9]. In melanoma,
GRM1 has been deemed both necessary and sufficient for melanocyte
transformation [10].
In melanoma, the PI3K/AKT/mTOR signaling cascade is often
constitutively activated. Approximately 70% of melanomas show aberrant
activation of pS6 that is a downstream target of mTOR [2,11].
Hyperactivation of PI3K/AKT/mTOR pathway in melanoma has been
demonstrated to occur through mutations in NRAS or PTEN or by
activating G protein-coupled receptors such as GRM1 [12–14]. We have
shown that AKT is one of the downstream targets of GRM1, which
promotes cellular transformation through autocrine (or possibly paracrine)
activation regardless of PTEN or NRAS mutational status [15–17].
On the basis of these previous studies, we hypothesized that small
molecules that disrupt autocrine glutamate signaling may potentially
be an effective therapy for melanoma patients. Riluzole (2-amino-6-
trifluoromethoxybenzothiazole) is a glutamate release inhibitor for the
treatment of amyotrophic lateral sclerosis. Riluzole has many
favorable properties that allow it to be translated from the bench to
the clinic: it is orally available, has low toxicity at high doses, and has
been well characterized by previous amyotrophic lateral sclerosis
studies (with FDA approval) [18,19]. Our previous preclinical
studies have shown that riluzole blocks the growth and invasion of
GRM1-positive melanoma cells by disrupting the glutamatergic
pathway leading to G2/M arrest followed by apoptosis [17,20]. We
have also found that by inhibiting glutamate release, riluzole
increases intracellular oxidative stress and causes DNA damage [21].
These earlier observations were translated into a phase 0 clinical trial
of riluzole for patients with late-stage melanoma, which showed a
34% molecular and clinical response [22].
Although riluzole is a promising therapeutic candidate for patients
with melanoma, it is unlikely that riluzole alone will be an effective
therapy for all patients with melanoma. While initial trials with riluzole
had shown positive results, results from phase II riluzole clinical trials
show that 12 of 13 patients treated did not meet Response Evaluation
Criteria In Solid Tumors (RECIST) criteria for response (unpublished,
personal correspondence). Riluzole has a variety of molecular targets
including autocrine/paracrine effects on glutamatergic signaling,
modulation of voltage-gated ion channels, and changes in expression
of glutamate transporters (i.e., ionic channels) [23]. However, many of
riluzole’s pharmacological actions are still poorly understood. Addi-
tionally, patients may have a wide range of exposure to riluzole as serum
levels have been shown to have high rates of interindividual variability at
similar dosing schedules [18]. This may limit riluzole as an effective
monotherapy for the majority of patients.
Small-molecule single-agent therapies, aiming at specific molecular
targets in growth/survival pathways in human cancers, have often
proved to be disappointing in clinical trials [24,25]. This is likely due
to feedback activation mechanisms, in melanoma, allowing cells to
reactivate signaling networks and escape cell death [26–28]. For
example, vemurafenib, a small molecule inhibiting mutated BRAF,
improved overall survival for several months in most melanoma
patients with mutated BRAF. Despite these advances, the clinical
responses are not durable and relapse of melanoma is a near certainty.
Our group previously reported that in vitro riluzole treatment
decreases cell growth of melanoma with wild-type PI3K pathway
activation. However, melanoma cell lines harboring constitutive
activating mutations of the PI3K pathway (e.g., PTEN and NRAS
mutations) showed only a minimal decrease in colony formation and
size in soft agar with riluzole treatment. Melanoma cells harboring
these mutations in the PI3K cascade (PTEN or NRAS) also showed
reactivation of the PI3K/AKT pathway with long-term riluzole
treatment [20]. We hypothesized that in patients with mutated PI3K
pathway, activation of the PI3K/AKT pathway may be responsible for
failure to respond to riluzole therapy. On the basis of the results of the
completed phase 0 trial and preliminary phase II results, we designed
the following study to assess the consequences of simultaneously
targeting GRM1 and PI3K signaling cascades.
Materials and Methods
Cell Tissue Culture, Pharmacological Compounds, and Antibodies
Melanoma lines UACC903 and UACC930 were grown in RPMI
1640 (Invitrogen, Carlsbad, CA) containing 10%FBS and 1%penicillin,
streptomycin, and amphotericin (Thermo Scientific, Logan,UT). C8161
cells were grown in Dulbecco's modified Eagle's medium (Mediatech,
Manassas, VA) with 10% FBS and 1% penicillin, streptomycin, and
amphotericin. SKMEL2 cells were grown in minimal essential media
(AmericanTypeCultureCollection,Manassas, VA) containing 10%FBS
and 1% penicillin, streptomycin, and amphotericin. HT144 was grown
in McCoys5A (Invitrogen) containing 10% FBS and 1% penicillin,
streptomycin, and amphotericin. All the cell lines were maintained in a
humidified incubator at 37°C and 5% CO2.
Pharmacological reagents, riluzole, and API-2 were obtained from
Tocris (Ellisville, MO), and rapamycin was obtained from LC
Laboratory (Woburn, MA). The choice of riluzole dose was based on
previous experiments (e.g., MTT and soft agar assays) across multiple
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melanoma cell lines. Our group had observed that ≤10 μM riluzole
had minimal effects on cell death or proliferation [17,20]. Yet, treatment
with 10 μM riluzole led to feedback loop activation of the PI3K
pathway. In previous experiments, we observed significant increased cell
death at doses of riluzole ≥25 μM. Given that 10 μM riluzole is a dose
that has shown PI3K pathway reactivation, without significant effects on
cell survival, this was chosen as low-dose riluzole. This is an advantageous
dose to see if the addition of a PI3K inhibitor may affect survival by
decreasing PI3K pathway activation.
Anti–phosphorylated AKT, anti-AKT, anti–phosphorylated Extracel-
lular signal-regulated kinases (ERK1/2) (Thr202, Tyr204), anti-ERK,
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), anti–phospho-
S6K, and phospho-mTOR (Ser2448) antibodies were obtained fromCell
Signaling Technology (Danvers, MA).
Soft Agar Colony Assays
One milliliter of a hard agar mixture (final concentration: RPMI
1640, 10% FBS, 10% MCDB 153, and 0.75% agar) was laid into
each well of a 12-well tissue culture plate and allowed to harden. Cells
were then trypsinized and suspended in a 600-μl soft agar RPMI
1640 mixture with final concentration of 10% FBS, 10% MCDB
153, and 0.35% agar that was overlaid onto the hard agar layer.
Vehicle or pharmacological reagents were incorporated into both
layers at appropriate concentrations. The colonies were fed with
250 μl of RPMI 1640 containing appropriate pharmacological
reagents every 2 days. Colonies were allowed to form in soft agar
layer for up to 3 weeks; afterward, three representative photographs
(Infinity Camera, Ottawa, Ontario) were taken. The number of
colonies and sizes were analyzed by ImageJ.
Protein Extraction and Western Blot Analysis
Protein lysates were prepared with a modified NP-40 lysis buffer that
contained the following: 25 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1 mM DTT, 0.5% NP-40, 10% glycerol, complete
protease inhibitor tablets (Roche, Indianapolis, IN), 1 mM PMSF, 50
mM β-glycerol phosphate, 10 mM p-nitrophenyl phosphate, 2.5 mM
sodium pyrophosphate, 100 nM okadaic acid, 10 mM sodium fluoride,
1 mM sodium orthovanadate, and 10 μM phenylarsine oxide.
Protein concentrations were quantified using the bicinchoninic
acid assay (BCA) method (Bio-Rad, Hercules, CA). Routinely, 25 μg
of protein was run on either 4% to 12% Tris-HCl gradient gels (Bio-
Rad) or 4% to 20% Bis-Tris Criterion gradient gels (Bio-Rad).
Proteins were transferred to either 0.2-μm polyvinyl difluoride
(PVDF) or 0.45-μm nitrocellulose membranes. Membranes were
blocked and incubated with primary antibodies according to standard
Western blot analysis protocols. Subsequent to primary antibody
binding, membranes were incubated with the corresponding HRP-
conjugated secondary antibody. The proteins were detected by
chemiluminescence (GE Healthcare, Piscataway, NJ) with exposure to
X-ray or detected in theG-Box system (Syngene, Frederick,MD). Band
intensities were analyzed with Gene Tools software (Syngene). Raw
volume with background subtracted was normalized to GAPDH, with
vehicle-treated cells set as 100%.
Nanoculture Plate System
Briefly, NanocultureMedia-50M (NCM-50M; B-Bridge International,
Cupertino,CA) containing10%FBS and1%penicillin, streptomycin, and
amphotericin was heated to 37°C and 500 μl was plated into each well of a
24-well, low-affinity binding, square or honeycomb Nanoculture plate
(B-Bridge International). The plates were spun at 500g for 3 minutes.
Afterward, cells were trypsinized and suspended in 500 μl ofNCM-50M
and added to each well. Cells were allowed to form spheroids for 2 to
4 days. Subsequent to spheroid formation, cells were treated with
pharmacological inhibitors or vehicle for 8 to 18 hours. At the end of
treatment, spheroids were harvested from each well with gentle
pipetting, spun, and washed with 1× Dulbecco Phosphate-Buffered
Saline (DPBS, Invitrogen) containing 10 mM sodium fluoride and
1 mM sodium orthovanadate. Cell pellets were subsequently lysed with
modified NP-40 lysis buffer described above and protein was collected.
Xenograft
Cells (1 × 106) of either C8161 or UACC903 were subcutaneously
injected into both flanks of 20-g, 6-week-old male, NCI NU/NU
mice. Tumors were allowed to reach 6 to 10 mm3 and randomized
into one of the following treatment groups: vehicle, riluzole (7.5 mg/kg),
rapamycin (1 mg/kg), or riluzole (7.5 mg/kg) combinedwith rapamycin
(1 mg/kg). For combinational drug treatment, pharmacological agents
were prepared in a single solution (1% PEG 8000 and 1% Tween 20)
and given intraperitoneally to mice every day. Tumor size was measured
for 15 days for C8161 and 17 days for UACC903. At the end of the
experiment, animals were sacrificed and tumor samples were harvested
for analysis. Tumor volume was calculated by measuring the width (w)
and length (l), the shortest and longest diameters, respectively, and using
the formula: V (volume) = w2 × l/2 [29]. The maximum and
minimum tumor values for each treatment arm at each time point
were disregarded because of differences in starting tumor volume.
Protein was extracted from tumors by a standard protocol for Western
blot analysis. This study was carried out in strict accordance with the
recommendations of the Institutional Animal Care andUse Committee
of the Cancer Institute of New Jersey.
Statistics
Analysis of variance (ANOVA) was used when comparing multiple
means within a group with a value of P b .05 considered statistically
significant. Scheffé post hoc test was used to assess the significance of
mean differences between each treatment group in colony assays.
Results
Previously, our group has shown that the glutamate inhibitor, riluzole,
and the non-competitive GRM1 antagonist, BAY 36-7620, were able to
hinder anchorage-independent growth of various GRM1-positive
melanoma cell lines [20]. However, those cells harboring activating
mutations in the PI3K pathway were not as responsive to riluzole
treatment. Hence, we wanted to extend our understanding of melanoma
cell resistance by combining riluzole with other inhibitors of the PI3K
pathway including rapamycin, an mTOR inhibitor, and API-2, an AKT
inhibitor. Melanoma cell lines were chosen by their mutational status
(C8161GRM1+,BRAF/NRAS/PTENWT, UACC903GRM1+,BRAFV600E,PTENMUT,
HT144GRM1+,BRAFV600E,PTENMUT, SKMEL2GRM1+,NRASQ61R,PTENWT,
and UACC930GRM1-,BRAFV600E,PTENMUT) and were treated with low
doses of inhibitors: 10 μM riluzole, 1 μMAPI-2, or 2.5 nM rapamycin
alone or in combination using soft agar anchorage-independent assays.
As shown in Figure 1A, regardless of PI3K mutational status, all
melanoma cell lines tested formed significantly fewer colonies with
combinational drug treatment. As previously reported, UACC930, a
GRM1-negative melanoma cell line, was not responsive to riluzole
treatment (negative control, Figure 1A). ANOVA for colony data
in Figure 1 revealed that there is a significant difference between the
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colony treatment groups across each cell line (F(5,84) = 75.591,
P b .001; Figure 1B).
In the GRM1-positive cell lines, low dose of riluzole led to
statistically significant reduction in the number of colonies (P b .05),
except UACC903, which showed an increase in the number of colonies
formed with riluzole treatment (Figure 1B). In general, response to
riluzole was less effective in PTEN-mutated cell lines compared to the
WT cell line. Treatment with either API-2 or rapamycin led to a
reduction in the number of colonies formed in all cell lines by 25% to
50% and 10% to 40%, respectively, except UACC903 that was not
altered in colony number in the presence of rapamycin (Figure 1B).
However, when riluzole is combined with either API-2 or rapamycin, a
significant decrease in the number of colonies formed was detected
for all cell lines by 50% to 90% in comparison with vehicle (DMSO)
controls. Scheffé post hoc test was used to assess the significance ofmean
differences between each treatment group in the colony assays. Results
of this analysis indicate that each combinatorial treatment had a
statistically significant difference compared to single treatment or
DMSO (P b .05; Figure 1B). UACC903 had an approximately 90%
decrease in colony number in response to combinational therapy. This
was particularly striking since UACC903 did not respond effectively to
single treatments of low-dose riluzole or low-dose rapamycin.
Figure 1. Riluzole combined with API-2 and rapamycin inhibits anchorage-independent growth of melanoma cell lines. Soft agar colony
assays were performed with C8161 (1 × 104 cells), UACC903 (1.5 × 104 cells), HT144 (1.5 × 104 cells), SKMEL2 (1.5 × 104 cells), and
UACC930 (5 × 104 cells) in the presence of one of the following low doses of inhibitors: vehicle (DMSO), 10 μM riluzole, 1 μMAPI-2, 2.5 nM
rapamycin, 10 μMriluzole combinedwith 1 μMAPI-2, or 10 μMriluzole combinedwith 2.5 nM rapamycin. Three representative photographs
were taken of each treatment (A). The number of colonies from three representative photomicrographs was totaled and colony-forming
potential relative to DMSO-treated cells was determined (B) as well as the size distribution of colonies (C). Experiments were repeated with
each cell line three times, with the exception of UACC930 (negative control, one experiment). ANOVA revealed that there is a significant
difference between the colony treatment groups across cell lines (F(5,84) = 75.591, P b .001). Scheffé post hoc test indicates that each
combinatorial treatment had a statistically significant difference compared to single treatment or DMSO across cell lines (P b .05).
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In addition to evaluating the changes in colony number, we also
assessed modulations in colony sizes. Changes in colony size were
most dramatically seen in C8161 and UACC903 with combina-
tional treatment. The vehicle-treated colonies for C8161 and
UACC903 show a large distribution indicating a large range in
colony size (Figure 1C). However, combinational treatment in
C8161 and UACC903 cells demonstrated smaller curves with a
much smaller distribution than control or individual treatments,
indicating that combinational treatments were very effective in
reducing both the number of colonies and the distribution of colony
sizes for both cell lines (Figure 1C). Alterations in colony size were
less prominent in HT144 and SKMEL2 melanoma cell lines. Both
lines had a relatively small average colony size and a small size
distribution. However, in HT144, there is a smaller colony size
distribution curve with either combinational treatment compared to
single agent treatments or vehicle. In SKMEL2, only riluzole combined
with API-2 decreased the number of large colonies.
Both the PI3K and Mitogen-activated protein kinase (MAPK)
pathways have been shown to be essential for anchorage- independent
growth, cell survival, transformation, and endothelial mesenchymal
transition in melanoma [11,30]. Activation of GRM1 by its ligand or
other agonists has been shown to activate both the PI3K and MAPK
cascades in melanoma [15,16]. Previously, we have shown that
25 μM riluzole was effective at decreasing phospho-AKT and
phospho-ERK1/2 levels within 6 hours. However, feedback loop
activation is often present in cells harboring mutations in the PI3K/
MAPK pathway, and longer treatments (N18 hours) with riluzole had
reactivation of the PI3K/MAPK in cell lines harboringmutations in those
pathways [20]. Therefore, we wanted to explore the effects of long-term
(N18 hours) combination drug treatment on signaling in the PI3K/
MAPK cascade in cell lines with various genetic backgrounds.
In our monolayer system, C8161, treated with single-agent low-dose
riluzole, showed a decrease in pAKT levels (Figure 2, A and B).
However, UACC903, HT144, and SKMEL2 showed an increase in
pAKT levels after 18 hours of low-dose riluzole treatment. In
UACC903, there was an approximately 1.5-fold increase in pAKT
levels after riluzole treatment (Figure 2B). UACC930, as previously
reported, showed minimal change in pAKT levels after the 18-hour
riluzole treatment (Figure 2A) [20]. Additionally, this low dose of riluzole
treatment appeared to have minimal effects on phospho-ERK1/2 levels
across all the cell lines (Figure 2A).
API-2 as a single agent or combined with riluzole led to a substantial
reduction in AKT activation in all cell lines relative to vehicle (DMSO)–
treated cells (Figure 2, A and B). Similar to riluzole, API-2 appeared
to have little or no effect on phospho-ERK1/2 levels with long-term
treatment across all cell lines tested.
C8161 cells treated with rapamycin had a decline in pAKT levels
by 30% to 50%. In contrast, single-agent rapamycin treatment in
UACC903 showed a 1.5- to 2-fold increase in pAKT levels (Figure 2B).
Surprisingly, the combination of riluzole and rapamycin in UACC903
showed no significant alteration in pAKT activation compared to
single-agent rapamycin treatment (Figure 2, A and B). In the presence
of rapamycin alone, there was an increase in pAKT levels in HT144,
SKMEL2, and UACC930 melanoma cell lines. In those three
melanoma cell lines, the addition of riluzole to rapamycin did not
appear to alter pAKT levels (Figure 2A).
On the basis of the results of our soft colony assays and our
monolayer signaling work, we decided to further test riluzole combined
with rapamycin in a xenograft model. We chose rapamycin because of
its current clinical applications and translational capacity into the clinic.
The ability to transfer API-2 to the clinicmay be limited by dose toxicity
as seen in clinical trials [31–33]. Currently, isoform-specific Akt
inhibitors are in clinical development.We chose C8161 andUACC903
for our xenograft model because they represent WT (PTENwt) and
hyperactivation (PTEN−/−) of PI3K pathway, respectively. Furthermore,
UACC903 has a genetic profile that is most commonly seen in
melanoma patients: GRM1+, NRASWT, BRAFV600E, and PTEN
mutation/epigenetic silencing. Unfortunately, we have been unable to
find a GRM1-negative melanoma cell line that will form tumors in
athymic nude mice as a control. Our xenograft model showed that
both riluzole and rapamycin alone and in combination are effective
at slowing tumor progression in both C8161 and UACC903
(Figure 3). The combination of riluzole and rapamycin was
statistically different than either single agent alone in both xenograft
models based on ANOVA (P b .05). This indicates that there
is a benefit to combinatorial therapy in the xenograft model, as
visualized on the box plot (Figure 3).
To further determine the effects of riluzole and rapamycin
combinatorial treatment on melanoma signaling, we extracted protein
from excised tumors in our xenograft model and probed for PI3K
signaling markers. Results revealed that in C8161, single-agent
riluzole treatment greatly decreased pAKT and downstream pS6
activation (Figure 4, A and B). Single-agent rapamycin treatment in
C8161 tumors had little effect on pAKT activation but significantly
inhibited downstream mTOR signaling (pS6 activation). The
combination of riluzole and rapamycin did not decrease pAKT
activation. However, downstream pS6 was inactivated similar to the
results observed for single-agent rapamycin treatment (Figure 4A). In
UACC903 xenograft tumors, single-agent riluzole appeared to have
minimal effects on pAKT levels and led to only slight reduction in
pS6 activation (Figure 4, A and B). Single-agent rapamycin led to a
noticeable decrease in pAKT and pS6 activation. The combination of
riluzole and rapamycin treatment in UACC903 xenografts led to
dramatic inhibition in levels of activated AKT than either single agent
alone (Figure 4, A and B). However, combinatorial treatment did not
result in further reduction in levels of pS6 activation (Figure 4A).
Western blot analysis revealed no change in p-ERK levels or
β-galactosidase (senescence) markers with combinational treatment
(data not shown).
Results from our in vivo tumor signaling appeared contrary to our
monolayer protein work. This is not surprising because often cellular
signaling is different between monolayer culture and in vivo
xenografts. In addition, recovering cells from soft agar or three-
dimensional (3D) collagen systems may be time consuming or cost
inefficient. Therefore, we adopted a 3D culture model in a
nanoculture plate system that allows us to perform 3D culture with
normal cell culture techniques as previously described above. After
allowing cells to form spheroids in culture, they were treated for
18 hours with vehicle, 10 μM riluzole, 2.5 nM rapamycin, or a
combination of both (Figure 4C). These experiments were only
performed with UACC903 because C8161 melanoma cells could not
be induced to form spheroids in our nanoculture plate system. Results
show that UACC903 cells treated in this 3D system have a signaling
profile very similar to the xenograft PI3K signaling results—pAKT
levels are reduced with combinational treatment (Figure 4D). This is
in contrast to the monolayer results of riluzole and rapamycin
combinational therapy, which showed no change in pAKT levels with
combinational therapy (Figure 2B).
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Discussion
The PI3K pathway is critical because it is a master regulator of
proliferation and survival signaling [34]. Constitutive activation of the
PI3K pathway has been shown to lead to the progression of malignant
disease [35]. In malignant melanoma, the PI3K/AKT signaling
cascade is one of the most frequently dysregulated pathways [11,36].
Unfortunately, single-agent therapy targeting the PI3K pathway
in melanoma has proven disappointing in clinical trials [24]. We
speculate that these monotherapy trials have failed because melanoma
cells have multiple, non-redundant ways of activating the PI3K
Figure 2. Steady-state effects of riluzole combinatorial therapy on the PI3K/MAPK pathways. C8161, UACC903, HT144, SKMEL2, and
UACC930 human melanoma cell lines were plated at 8 × 105 on a 60-mm dish and allowed to recover o/n. The following day, cells were
treated with either vehicle (DMSO), 10 μM riluzole, 1 μM API-2, 2.5 nM rapamycin, 10 μM riluzole combined with 1 μM API-2, or 10 μM
riluzole combined with 2.5 nM rapamycin for 18 hours. The 18-hour treatment time point was chosen because previous work has shown
that that is adequate time for feedback loop activation to take place inmelanoma cell lines in vitro and is representative of steady state [20]
(A). Band intensities were analyzed with Gene Tools software (Syngene). Raw volume of pAkt and total Akt with background subtracted
was normalized to GAPDH, with vehicle-treated cells set as 100%. The mean ratio of pAkt/Total Akt for C8161 (triplicate) and UACC903
(duplicate) is shown for each single-agent and combinational therapy (B).
6 Targeting Glutamatergic Signaling and PI3K Pathway in Melanoma Rosenberg et al. Translational Oncology Vol. 8, No. 1, 2015
pathway—each mutation giving each melanoma cell a distinctive
survival advantage [37]. As previously mentioned, GRM1 overactiva-
tion, NRASQ61Rmutations, and PTEN silencing are all multiple ways
of hyperactivating the PI3K pathway. Because these mutations may be
seen within the same melanoma cell, each mutation likely confers a
selective advantage for that melanoma. For any combinatorial treatment
to be effective, each aberration or mutation should be blocked effectively
to limit tumor growth. Interestingly, the most common BRAFV600E
mutation in melanoma appears to have minimum or no effect on the
susceptibility of melanoma cells to riluzole combined with mTOR
inhibition. Our data showed that the combinational treatment was
efficient in reducing PI3K signaling cascades, cell proliferation in vitro
2D and 3D systems, and in vivo xenografts.
Rapamycin, an mTORC1 inhibitor, has been shown to inhibit
melanocyte growth but has also been shown to increase feedback loop
activation of pAKT. Rapamycin blocks the mTORC1 complex
(rapamycin-sensitive complex), leading to increased mTORC2
activation, which has been shown to phosphorylate AKT across
multiple different cancer cell lines [38,39]. Differential sensitivity to
mTOR inhibitors or combinational therapy was not evident by
alterations in upstream (pAKT levels) or downstream (pS6 levels)
PI3K pathway activation. It has been previously reported that
downstream inhibition of pS6 levels does not explain differences in
sensitivity to mTOR inhibition [40]. In our xenograft model of WT
PI3K activation (C8161), pAKT levels did not correlate with tumor
size, where a modest decrease in pAKT levels yielded significant
reduction in in vivo tumor progression. However, in the xenograft
model of UACC903 cells harboring an overactive PI3K pathway
(PTEN mutation), tumor size appears to be more closely correlated
with pAkt suppression. Taken together, these results suggest that
suppression of pAKT levels alone is not likely an ideal biomarker to
determine the efficacy of this combinatorial therapy. Werzowa and
colleagues also noted that the effectiveness of vertical inhibition of the
PI3K pathway across multiple melanoma cell lines did not seem to be
explained merely by pAKT levels [41]. Perhaps, pAKT levels can serve
as a biomarker in melanoma tumors that possess a mutated PI3K
pathway, because these melanoma cells are overly addicted to activated
PI3K pathway for growth and survival [40].
Alternatively, the bona fide alterations in PI3K signaling may not be
accurately reflected in these experiments because they were performed
in a monolayer (2D) system and there is no valid translation from
in vitro culture system to in vivo settings. Results from our signaling
experiments led us to conclude that there exists a disconnect between
monolayer signaling and in vivo tumor signaling with our combina-
tional drug treatments. This was confirmedwith repeating colony assays
and monolayer and nanoculture signaling experiments of riluzole
combined with another mTOR inhibitor, temsirolimus (Figure S1).
These data again showed a disconnect between monolayer and 3D
signaling. Our anchorage-independent assay and our nanoculture (3D)
signaling appear to more closely mimic xenograft tumor signaling
responses compared to our monolayer system. This is supported by
recent evidence that 3D drug treatments more often recapitulate in vivo
tumor biology [42,43]
Blocking two components within the same signaling pathway
is often referred to as vertical inhibition. Werzowa and colleagues
showed that targeting the PI3K pathway with PI-103, a PI3K class 1A
and mTORC1/C2 inhibitor, together with rapamycin was extremely
potent at halting melanoma progression [41]. Furthermore, Aziz and
colleagues demonstrated that vertical inhibition of the PI3K pathway
in melanoma successfully inhibits melanoma progression regardless of
BRAF mutational status, confirming our results [44]. This has led us
to hypothesize that melanoma cells are very sensitive to vertical
inhibition of the PI3K pathway, regardless of BRAF genotypes, which
implies that melanoma cells are overly dependent on this pathway for
growth and survival—e.g., oncogenic addiction to a pathway rather
than a particular signaling kinase. Targeting GRM1 and PI3K
together appears to effectively arrest melanoma progression in vivo
and in vitro—by targeting two positions within the pathway. Results
from our current studies strongly suggest that we were able to block
Figure 3. Riluzole combinedwith rapamycin effectively decreases
tumor burden in xenograft model. C8161BRAF/NRAS/PTEN WT and
UACC903BRAFV600E,PTENMUT cells were subcutaneously injected
into both flanks of 20-g, 6-week-old male, NC NU/NU mice.
Mice underwent treatment with either vehicle (DMSO), riluzole
(7.5 mg/kg), rapamycin (1 mg/kg), or riluzole (7.5 mg/kg) combined
with rapamycin (1 mg/kg). The final tumor volumes in each treatment
arm are shown in a box plot for C8161 (A) and UACC903 (B). The
combination of riluzole and rapamycin was statistically different than
single therapy by ANOVA (P b .05) in each xenograft.
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the PI3K pathway despite multiple pathway aberrations. The clinical
benefits of vertical inhibition in melanoma are beginning to be
realized. Recent clinical trials of vertical inhibition of the MAPK
cascade have already shown significant clinical benefit for patients
with metastatic melanoma [45].
Moving forward, we plan on pursuing a phase Ib/II clinical trial of
riluzole combined with mTOR inhibition in metastatic melanoma
patients, exclusive to patients with an overactive PI3K pathway, regardless
of BRAF mutational status.
Conclusions
Our results show that treatment of melanoma cell lines both in vitro
and in vivo, targeting glutamate signaling and mTOR inhibition,
leads to decreased anchorage-independent growth and xenograft
tumor progression regardless of PI3K pathway mutational status.
Additionally, melanoma cell lines harboring PI3K pathway mutations
are particularly susceptible to this combinational treatment. Our
experiments showed that nanoculture (3D) signaling more closely
resembles xenograft tumor signaling than a monolayer (2D) system.
Therefore, further combinational drug research in melanoma should take
into account the differences in cellular signaling pathways associated with
different experimental model systems (3D vs 2D).
The response of melanoma cells to this combinatorial treatment
(riluzole and mTOR inhibition) is independent of BRAF mutational
status. Therefore, this combination of agents may be a viable alternative
for late-stage melanoma patients who are BRAF WT and are therefore
ineligible for vemurafenib therapy, which accounts for approximately
50% of the melanoma patient population.
Figure 4. Tumor PI3K pathway signaling with combinational riluzole therapy compared with nanoculture (3D) modeling. Effects on the
PI3K pathway in each xenograft model (C8161 or UACC903) were determined with each treatment: vehicle, riluzole, rapamycin, or
combinational therapy. A representative sample of each treatment arm is displayed from both tumor cell lines. pAKT, total AKT, and
GAPDH expression levels were quantified using Gene Tools software (Syngene) for each xenograft tumor shown in A. For each cell line,
the pAKT/total AKT is reported, normalized to GAPDHwith vehicle (DMSO) treated reported as 100% (B). UACC903 cells were also plated
into the nanoculture plate system and allowed to form spheroids for 2 days. Afterward, cells were treated with (I) vehicle, (II) 10 μM
riluzole, (III) 2.5 nM rapamycin, and (IV) combinational treatment for 18 hours (C). Lysate from the nanoculture plate experiments was
collected and underwent Western blot analysis to look at changes in the PI3K pathway (D). Results revealed that nanoculture (3D)
modeling of combinational drug treatment significantly resembled in vivo xenograft results.
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